Continuing Education Activity

Toxic megacolon is a rare, life-threatening complication of severe colonic inflammation characterized by nonobstructive colonic dilation accompanied by systemic toxicity. This course reviews the association of toxic megacolon with inflammatory bowel disease or Clostridioides difficile infection, although numerous infectious, inflammatory, ischemic, and medication-related conditions may precipitate the disorder and its clinical features, established diagnostic criteria, appropriate imaging, and supportive and disease-specific therapy that are essential to prevent perforation, sepsis, multiorgan failure, and death. This activity outlines the epidemiology, pathophysiology, and risk factors for toxic megacolon. This activity for healthcare professionals is designed to enhance the learner's competence in identifying patients at risk, interpreting laboratory and imaging findings, recognizing indications for intensive monitoring and urgent surgical consultation, selecting timely evidence-based medical and surgical management of toxic megacolon, and implementing an appropriate interprofessional approach when managing this condition to improve patient outcomes and reduce morbidity and mortality.

Objectives:

• Identify patients at risk for toxic megacolon.
• Differentiate toxic megacolon from other causes of acute abdominal pain based on diagnostic criteria.
• Determine when urgent surgical consultation is indicated for toxic megacolon based on clinical factors.
• Collaborate with interprofessional team members to improve care coordination and outcomes in patients with toxic megacolon.

Access free multiple choice questions on this topic.

Introduction

Toxic megacolon represents a rare but potentially fatal complication of severe colonic inflammation characterized by nonobstructive dilation of the colon accompanied by systemic toxicity. Colonic dilation may involve the entire colon or remain confined to a segment, yet systemic toxicity remains a defining feature of the condition. Inflammatory bowel disease (IBD) and Clostridioides difficile infection account for the most common underlying causes, although any inflammatory process affecting the colon has the potential to precipitate toxic megacolon.

Patients generally present with severe systemic illness, making early clinical recognition and prompt diagnosis critical for preventing progression to life-threatening complications and enabling rapid initiation of appropriate medical therapy. Failure to achieve an adequate response to medical management or development of complications, eg, colonic perforation, may necessitate urgent, life-saving surgical intervention.[1]

Etiology

Toxic megacolon may arise as a complication of any infectious colitis that produces significant colonic inflammation. The most common etiologies include IBD and infectious processes affecting the colon.[1][2]

Inflammatory Bowel Disease

Within IBD, ulcerative colitis represents a leading association, with toxic megacolon occurring more frequently in pancolitis, although segmental inflammatory disease may also progress to this complication.[3][4] Toxic megacolon complicates approximately 5% of acute severe ulcerative colitis (ASUC) cases.[5] Clinically, ASUC is defined by 6 or more stools per day accompanied by at least 1 systemic toxicity feature, including fever, tachycardia, elevated C-reactive protein (CRP), elevated erythrocyte sedimentation rate (ESR), or hemoglobin less than 10.5 g/dL.[6] Crohn disease involving the colon is also an important contributor to the risk of toxic megacolon. Please see StatPearls' companion resource, "Crohn Disease," for further information.

Infectious Causes

Clostridioides difficile (C difficile) colitis represents the most common infectious cause of toxic megacolon.[5][7] The incidence of toxic megacolon associated with C difficile colitis has increased over recent years. Up to 1990, reported proportions rose from 0.4% to 3%; after 1990, rates increased further to 4.3%.[8]  Asymptomatic C difficile infection affects approximately 20% of hospitalized patients, whereas symptomatic infection occurs in approximately 1%.[9][10] Community-acquired infections have become increasingly prevalent and account for nearly one-third of all C difficile cases.[11][12] In addition, nearly 50% of patients with ASUC present with concurrent C difficile infection, highlighting the importance of routine evaluation for coinfection in this population.[13] 

Additionally, cytomegalovirus (CMV) colitis coexists in up to a third of ASUC cases that fail to respond to intravenous corticosteroids.[14] CMV is also the leading cause of toxic megacolon in HIV and AIDS patients, especially in those who have disseminated CMV.[11] Other infectious causes of toxic megacolon include:

• Rotavirus
• Salmonella spp.
• Shigella
• Yersinia
• Campylobacter jejuni colitis
• Escherichia coli: Enterohemorrhagic O157:H7 (produces Shiga toxins and can lead to hemolytic-uremic syndrome) or enteroaggregative strains
• Entamoeba histolytica
• Cryptosporidium
• Invasive aspergillosis

Additional Etiologies of Toxic Megacolon

Ischemic colitis is a relatively rare cause of toxic megacolon. Some additional factors that can precipitate toxic megacolon include:

• Hypokalemia
• Medications (eg, antimotility agents, opiates, anticholinergics, antidepressants, methotrexate)
• Colonoscopy, bowel preparations, and barium enema in an inflamed colon
• Neutropenic colitis
• Radiation colitis
• Graft versus host disease
• Lymphoma of the colon
• Hirschsprung disease
• Behçet syndrome
• Kaposi sarcoma
• Hirschsprung disease [15]
• Collagenous colitis [16][17]

Epidemiology

The incidence of toxic megacolon in the general population remains unknown. Toxic megacolon may occur in males and females across all age groups; however, individuals with IBD represent the highest-risk population.[18] IBD accounts for approximately 48% of toxic megacolon cases.[16]

In Crohn colitis, toxic megacolon tends to develop earlier in the disease course, before the establishment of significant fibrosis. Once severe fibrosis develops, the colon loses distensibility, limiting its ability to dilate markedly.[19] In contrast, the incidence of toxic megacolon in ulcerative colitis exceeds that observed in Crohn colitis, occurring in approximately 8% to 10% of ulcerative colitis cases compared with approximately 2.3% of Crohn colitis cases.[1] This disparity has been attributed to the transmural inflammation characteristic of Crohn disease, which tends to limit extreme colonic dilation, whereas ulcerative colitis more readily permits substantial colonic expansion.

Pathophysiology

The pathogenesis of toxic megacolon remains incompletely understood. However, one proposed mechanism indicates that mucosal inflammation initiates the disease process. This inflammatory response releases inflammatory mediators and bacterial products, leading to increased expression of inducible nitric oxide synthase, which subsequently elevates nitric oxide levels and promotes colonic dilation.

Evidence supporting this mechanism includes a study that demonstrated markedly elevated levels of inducible nitric oxide synthase in the muscularis propria of patients with toxic megacolon, reinforcing the proposed role of nitric oxide–mediated smooth muscle relaxation and dilation.[20] In addition, toxic megacolon involves inflammation of the colonic smooth muscle, resulting in progressive neuromuscular dysfunction, paralysis of the bowel wall, and eventual colonic dilation.[21]

Histopathology

The histology of surgically resected colonic specimens typically reflects the underlying cause of colitis.[1] Pseudomembranes are characteristically present in C difficile colitis. Dilation of the colon, thinning of the wall, and deep ulcers are gross features that toxic megacolon shares with IBD and other types of colitis. Toxic megacolon features extensive mucosal injury with erosion or ulceration, dense acute inflammatory infiltrates that may involve deeper layers of the bowel wall, variable degrees of necrosis, and mucosal sloughing.[22] The muscle fibers are usually shortened and rounded with collections of eosinophilic cytoplasm, and the distal colon shows destructive changes in the myenteric plexus.[3]

History and Physical

Clinical History

The medical history of a patient often identifies key risk factors, eg, IBD, including ulcerative colitis and Crohn colitis, while comorbid conditions, eg, diabetes and renal failure, commonly appear in affected patients. Medication history and environmental exposures frequently assist clinicians in narrowing the differential diagnosis and guiding appropriate evaluation. Pharmacologic agents may significantly influence clinical presentation, with corticosteroids capable of masking the full severity of toxic megacolon, whereas anticholinergics and opioids may exacerbate colonic dilation and clinical deterioration.[17] Presentation with diarrhea, abdominal pain, and abdominal distension should heighten clinical suspicion for toxic megacolon. Weight loss commonly occurs at the time of diagnosis due to malabsorption, nutrient loss from intestinal and systemic inflammation, fluid depletion from diarrhea, reduced oral intake, and vomiting.

Patients with toxic megacolon commonly present with severe abdominal pain, marked abdominal distension, nausea, vomiting, and diarrhea that may or may not be bloody, often accompanied by malaise or altered sensorium. In a study of patients with Clostridioides difficile infection complicated by toxic megacolon, the 3 most frequent presenting complaints included diarrhea, malaise, and abdominal pain with distension.[23] Features suggestive of peritonitis, including fever and severe abdominal pain, may indicate bowel perforation.[24] Persistent fever for 2 to 3 days during corticosteroid therapy should raise concern for possible perforated bowel and prompt urgent reassessment.[1]

Physical Examination

Physical examination frequently reveals a critically ill patient with fever, tachycardia, and hypotension. Abdominal findings typically include distension, focal or diffuse tenderness, and decreased bowel sounds.[17][23] The presence of involuntary guarding or rebound tenderness in a patient with hypotension and altered mental status should raise immediate concern for colonic perforation and require urgent surgical evaluation.

Evaluation

The most commonly used diagnostic criteria for toxic megacolon require all of the following:

• Radiographic evidence of the dilation of the colon to >6 cm, particularly in the transverse and ascending colon

• At least 3 of the following:
  • Fever over 38 °C
  • Heart rate >120 beats/min
  • Neutrophilic leukocytosis >10,500/µL
  • Anemia

• At least 1 of the following:
  • Altered sensorium
  • Hypotension
  • Hypovolemia
  • Electrolyte abnormalities [18]

Laboratory Studies

Laboratory results often show anemia and primarily leukocytosis with a left shift, although immunocompromised patients and some with sepsis may be neutropenic.[25] Metabolic acidosis is indicative of ischemic colitis, and diarrhea may cause hypokalemia and metabolic alkalosis. Increased inflammatory markers, eg, C-reactive protein or erythrocyte sedimentation rate, are also commonly seen. Patients presenting with ASUC should have stool testing for concurrent C difficile infection.[13] Additional findings in sepsis include positive blood cultures, elevated procalcitonin, elevated serum lactic acid, and coagulopathy (thrombocytopenia, elevated D-dimer, and prolonged PT and PTT).

Diagnostic Imaging

Plain abdominal imaging remains the most frequently used modality and is essential for monitoring the course of toxic megacolon; it typically shows air distention of the proximal colon, air-fluid levels, and loss of normal haustral markings (see Image. Toxic Megacolon). Computed tomography (CT) is increasingly used, particularly because it provides more reliable information about disease severity. CT is commonly used to assess possible complications of toxic megacolon, which include abscess, perforation, ischemic/necrosis, or ascending pylephlebitis.[26] Key features visible on CT include colonic wall thickening, pericolic stranding, bands of high- and low-intensity stretching over thickened submucosal folds (accordion sign), and a multilayered appearance due to alternating densities of edematous submucosa and hyperemic mucosa, known as the target sign (see Image. Toxic Megacolon Imaging). An abdominal ultrasound is also an option, but it has limited utility, and findings tend to be nonspecific.[27]

Colonoscopy

Colonoscopy is contraindicated given the high risk of perforation in the setting of toxic megacolon. However, proctoscopy or sigmoidoscopy with minimal or no air insufflation can be performed to inspect the rectum and distal sigmoid colon for features of severe acute colitis due to IBD or C difficile infection. Some cases of CMV infection can be diagnosed in this way, although the infection may affect only more proximal portions of the colon.[28][29] 

Treatment / Management

The treatment of toxic megacolon focuses on medical management of the underlying cause of colitis, accompanied by supportive care to avoid or promptly recognize perforation, sepsis, and other life-threatening complications. Correction of electrolyte disturbances, rehydration, and symptom management are also essential components of effective medical management.[25]

Medical Management

Medical management is successful in about half of affected patients. Patients should be admitted to an intensive care unit for observation in case of unexpected deterioration. Intravenous (IV) hydration should be provided with electrolytes, based on laboratory results.[28][29] Nothing should be taken by mouth unless oral medication is required; however, as the patient continues to improve, they can gradually start eating to promote the restoration of the normal gut microbiota.[1] Any medications that might cause or exacerbate the condition should be discontinued. Initially, electrolytes, a complete blood count with WBC differential, and plain abdominal x-rays should be repeated twice daily until the clinical situation is stable, then daily.

Any medications that can aggravate the condition, eg, opioids and anticholinergics, should be discontinued. Due to the high risk of sepsis and perforation, patients should be placed on broad-spectrum antibiotics, especially if an infectious cause is suspected. If CMV is suspected, ganciclovir should be administered.[1] The antibiotics of choice for C difficile are oral vancomycin 500 mg 4 times a day and IV metronidazole 500 mg 3 times daily. If an ileus precludes oral vancomycin, it should be replaced with a 500 mg vancomycin enema administered rectally.[30]

Patients with severe acute ulcerative colitis should be given IV corticosteroids as soon as possible. Generally, the recommendation is hydrocortisone IV 100 mg every 6 hours or methylprednisone 60 mg daily for 5 days. Higher doses do not provide additional benefit.[28] Infliximab is a second-line therapy for patients with toxic megacolon and ASUC, Crohn colitis, or indeterminate colitis who fail to respond to IV corticosteroids, as evidenced by persistence of frequent loose stools, hypoalbuminemia, and elevated CRP or ESR. Cyclosporine is usually a second-line option for refractory ASUC (but not for Crohn's or indeterminate colitis) if infliximab is not tolerated.[3][4]

Surgical Management

The ideal timing of surgery in toxic megacolon patients is not necessarily predictable. If a perforation, bleeding, or clinical deterioration of the patient occurs, surgical intervention may be lifesaving. Nevertheless, some studies conclude favorable outcomes in patients in whom surgical intervention is done soon after making the diagnosis of toxic megacolon. In contrast, other studies show an increase in mortality, especially in patients older than 65.[31] Therefore, surgeons, internists and hospitalists, and gastroenterologists need to work together to assess the patient frequently.[1]

Inflammatory bowel disease

Surgery is indicated for IBD when a 3-day course of an IV corticosteroid, followed by a 3-day course of infliximab or cyclosporine, is ineffective in adequately treating toxic megacolon in the setting of acute severe IBD or fulminant colitis, or if toxic megacolon develops during treatment of severe acute colitis with either infliximab or cyclosporine.[32] Surgery should not be delayed in patients receiving steroids, as clinical signs of deterioration may be masked.

The current surgical treatment of choice is a subtotal colectomy with an end ileostomy, preserving the pericolonic mesentery and the IMA if possible, and creating a long rectal stump to be managed as a Hartmann pouch, subcutaneous placement of a closed rectal stump, or a mucous fistula.[33] Urgent surgery can be performed laparoscopically in experienced hands, but emergent cases are best performed via an open approach. Surgical mortality is 2% to 8%, but is 40% or more if colonic perforation has occurred.[34]

C difficile infection

Early surgery for toxic megacolon complicating fulminant C difficile infection may be lifesaving, either to prevent or to treat serious complications of peritonitis, perforation, and septic shock. Early surgery, performed before septic shock has developed, reduced the 30-day mortality in toxic megacolon complicating fulminant C difficile infection from 45% to 21%.[35] 

Indications for surgery for toxic megacolon complicating C difficile infection include any of the following:

• Sepsis
• Peritonitis
• Intra-abdominal hypertension
• Abdominal compartment syndrome
• Colonic full-thickness ischemia or necrosis
• Colonic perforation
• Ventilator-dependent respiratory failure
• Acute renal failure
• Persistent hypotension and shock despite resuscitation
• Progressive vasopressor-requiring hypotension
• Acute end-organ failure
• Relative indications: WBC >50,000 cells/mL or Serum lactate level >5 mmol/L [36]

The surgery of choice for C difficile-induced toxic megacolon is a laparoscopic diverting loop ileostomy with colonic antibiotic lavage, an operation associated with decreased mortality, performed when possible based on local expertise and familiarity with lavage. If intra-abdominal hypertension, abdominal compartment syndrome, colonic wall necrosis, or perforation are present, then laparotomy with a total abdominal colectomy or a subtotal colectomy is the preferred operation. A segmental resection is potentially problematic because it carries a 15% risk of reoperation.[36]

Table

A hospitalized patient receiving corticosteroids for severe colitis continues to have fever and worsening abdominal pain after 48 hours. What complications should be urgently considered at this point?

Differential Diagnosis

The differential diagnosis includes:

• Colonic pseudo-obstruction (Ogilvie syndrome) [37]
• Diffuse gastrointestinal dysmotility
• Hirschsprung disease
• Acquired megacolon [1][16]

Prognosis

Mortality rates are up to 80% when toxic megacolon is due to fulminant infection, but substantially lower (0% to 2%) when due to IBD, attributable to early recognition, prompt intervention, and better treatment of the underlying condition.[34][38][34] Colon perforation correlates with a worse prognosis, and it substantially increases mortality.[8][25] However, early surgery before septic shock, respiratory failure, or multiple organ dysfunction syndrome has developed substantially reduces mortality.[5][39]

A review of over 1,200 patients with IBD and toxic megacolon found the following to be risk factors for higher mortality:

• Female gender
• Age older than 40 years
• Hypoalbuminemia
• Elevated blood urea nitrogen level
• Metabolic acidosis [38]

Risk factors for higher mortality in C difficile infection complicated by toxic megacolon include:

• Ventilator-dependent respiratory failure
• Vasopressor-dependent shock
• Age older than 75 years
• Renal failure
• Electrolyte abnormalities
• Corticosteroid use [38]

Complications

Failure to provide timely and appropriate treatment for toxic megacolon markedly increases the risk of colonic perforation and other life-threatening complications. Disease progression may result in peritonitis, abscess formation, abdominal compartment syndrome, or frank perforation, each of which represents a surgical emergency requiring immediate operative evaluation and intervention.[1] Prompt recognition of clinical deterioration and rapid escalation of care remain essential to reduce morbidity and improve patient outcomes.

Untreated colonic perforation or disseminated infection associated with toxic megacolon carries a very high mortality rate. Early diagnosis, aggressive medical management, close clinical monitoring, and timely surgical intervention when indicated remain critical strategies for preventing catastrophic complications and improving survival.[1]

Consultations

Consultation with a gastroenterologist should occur as soon as toxic megacolon is considered in the differential diagnosis to confirm the diagnosis, determine the underlying cause of colitis when present, initiate appropriate medical therapy, and facilitate timely surgical consultation when indicated. Early specialist involvement supports rapid diagnostic evaluation, appropriate selection of medical treatment, and ongoing assessment of the patient's clinical response, all of which contribute to reducing the risk of life-threatening complications.

A limited endoscopic evaluation may provide diagnostic value in carefully selected patients. Brief inspection of the rectum and, when appropriate, the distal sigmoid colon using a colonoscope or sigmoidoscope without air insufflation may provide sufficient information to diagnose ulcerative colitis and certain other causes of proctitis while minimizing the risk of colonic perforation associated with more extensive endoscopic examination. If surgical consultation has not occurred at the time of hospital admission, consultation with a surgeon should follow immediately after the diagnosis of toxic megacolon. Early involvement of the surgical team facilitates prompt assessment for operative intervention should medical therapy fail, or clinical deterioration occur, allowing timely decision-making and improving coordination between medical and surgical management.

Deterrence and Patient Education

Patient education plays a central role in reducing the morbidity and mortality associated with toxic megacolon by promoting early recognition of warning signs and timely medical evaluation. Individuals should understand that toxic megacolon constitutes a medical emergency rather than a self-limited gastrointestinal condition. Education should emphasize that severe abdominal pain, progressive abdominal distension, persistent or worsening diarrhea, fever, tachycardia, vomiting, altered mental status, or signs of dehydration require immediate medical attention. Prompt diagnosis and treatment substantially reduce the risk of perforation, sepsis, multiorgan failure, emergency surgery, and death.

Patients with IBD, particularly ulcerative colitis and Crohn colitis involving the colon, require ongoing counseling regarding their increased risk of developing toxic megacolon during severe disease flares. Education should reinforce adherence to prescribed medical therapy, routine follow-up with gastroenterology, and early reporting of worsening gastrointestinal symptoms rather than delaying evaluation. Patients should also understand that medications that reduce intestinal motility, including opioids, anticholinergics, and certain antidiarrheal agents, may worsen colonic dilation and should not be used without clinician guidance during episodes of severe colitis.

Education should also address other potential causes of toxic megacolon, including Clostridioides difficile infection and other infectious colitides. Patients receiving antibiotics, those with recent exposure to healthcare, or individuals with immunocompromising conditions should recognize symptoms suggestive of infectious colitis and seek prompt assessment. Clinicians should encourage patients with severe acute ulcerative colitis to undergo recommended stool testing for concurrent C difficile infection and to comply with prescribed treatment plans and monitoring recommendations.

Preventive strategies depend on effective communication between patients and the interprofessional healthcare team. Physicians, advanced practitioners, nurses, pharmacists, and other healthcare professionals should reinforce consistent education regarding disease management, medication adherence, recognition of high-risk symptoms, and the importance of seeking emergency care rather than attributing progressive abdominal distension or pain to simple bloating. Repeated reinforcement during outpatient visits, hospitalizations, and discharge counseling supports earlier intervention, improves adherence to evidence-based management, and decreases the likelihood of preventable complications associated with toxic megacolon.

Pearls and Other Issues

Colitis due to IBD and C difficile infection are the most common causes of toxic megacolon. If the cause is found to be IBD without C difficile infection, medical therapy for colitis should be tried first. If it worsens or doesn't improve with steroids and/or with infliximab or cyclosporine, surgery is essential. By comparison, toxic megacolon due to C difficile tends to require surgery earlier in its course.

Toxic megacolon often requires surgery as a potentially lifesaving procedure, while non-toxic megacolon (Ogilvie syndrome) can be treated with medication, clinical maneuvers, and, in some cases, colonoscopic decompression and seldom requires surgery.

Patients with toxic megacolon should be admitted to an intensive care unit and monitored closely, as a delay in surgical intervention for clinical deterioration is associated with substantially higher morbidity and mortality.

Enhancing Healthcare Team Outcomes

Toxic megacolon is a life-threatening complication of severe colonic inflammation characterized by nonobstructive colonic dilation with systemic toxicity. Inflammatory bowel disease and Clostridioides difficile infection account for most cases, although infectious, ischemic, inflammatory, and medication-related conditions may also precipitate the disorder. Proposed pathophysiologic mechanisms include the release of inflammatory mediators, increased inducible nitric oxide synthase activity, smooth muscle paralysis, and progressive colonic dilation. Patients commonly present with severe abdominal pain, distension, diarrhea, fever, tachycardia, hypotension, and systemic illness. Diagnosis relies on clinical assessment, laboratory evaluation, and imaging that demonstrates colonic dilation, while colonoscopy remains contraindicated due to the risk of perforation. Management requires aggressive supportive care, treatment of the underlying cause, intensive monitoring, correction of electrolyte abnormalities, discontinuation of medications that impair colonic motility, and timely surgical intervention for perforation, refractory disease, ischemia, sepsis, or clinical deterioration.

Optimal outcomes depend on coordinated interprofessional management and continuous communication among healthcare professionals. Emergency physicians, hospitalists, gastroenterologists, intensivists, surgeons, and advanced practitioners collaborate to establish the diagnosis, initiate evidence-based therapy, monitor for complications, and determine the need for urgent operative intervention. Radiologists provide timely interpretation of diagnostic imaging, while nurses perform frequent assessments, recognize signs of deterioration, communicate changes in clinical status, and support critical care and postoperative recovery. Pharmacists review medication regimens, discontinue agents that reduce intestinal motility, optimize antimicrobial and anti-inflammatory therapy, and monitor for adverse drug effects. Shared decision-making among clinicians, patients, and families, combined with early surgical consultation, standardized monitoring, timely referral, coordinated follow-up, and systems-based communication, reduces delays in care, prevents perforation and multiorgan failure, and improves patient safety, quality of care, and clinical outcomes.

Review Questions

• Access free multiple choice questions on this topic.
• Click here for a simplified version.
• Comment on this article.

References

1.

Autenrieth DM, Baumgart DC. Toxic megacolon. Inflamm Bowel Dis. 2012 Mar;18(3):584-91. [PubMed: 22009735]

2.

Hommes DW, Sterringa G, van Deventer SJ, Tytgat GN, Weel J. The pathogenicity of cytomegalovirus in inflammatory bowel disease: a systematic review and evidence-based recommendations for future research. Inflamm Bowel Dis. 2004 May;10(3):245-50. [PubMed: 15290919]

3.

Desai J, Elnaggar M, Hanfy AA, Doshi R. Toxic Megacolon: Background, Pathophysiology, Management Challenges and Solutions. Clin Exp Gastroenterol. 2020;13:203-210. [PMC free article: PMC7245441] [PubMed: 32547151]

4.

Erratum: Toxic Megacolon: Background, Pathophysiology, Management Challenges and Solutions [Corrigendum]. Clin Exp Gastroenterol. 2021;14:309-310. [PMC free article: PMC8302810] [PubMed: 34321902]

5.

Liggett MR, Alam HB. Management of Severe Colitis and Toxic Megacolon. Clin Colon Rectal Surg. 2024 Nov;37(6):404-410. [PMC free article: PMC11466533] [PubMed: 39399135]

6.

Rubin DT, Ananthakrishnan AN, Siegel CA, Sauer BG, Long MD. ACG Clinical Guideline: Ulcerative Colitis in Adults. Am J Gastroenterol. 2019 Mar;114(3):384-413. [PubMed: 30840605]

7.

McDonald LC, Gerding DN, Johnson S, Bakken JS, Carroll KC, Coffin SE, Dubberke ER, Garey KW, Gould CV, Kelly C, Loo V, Shaklee Sammons J, Sandora TJ, Wilcox MH. Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin Infect Dis. 2018 Mar 19;66(7):e1-e48. [PMC free article: PMC6018983] [PubMed: 29462280]

8.

Ausch C, Madoff RD, Gnant M, Rosen HR, Garcia-Aguilar J, Hölbling N, Herbst F, Buxhofer V, Holzer B, Rothenberger DA, Schiessel R. Aetiology and surgical management of toxic megacolon. Colorectal Dis. 2006 Mar;8(3):195-201. [PubMed: 16466559]

9.

Hokama A, Ohira T, Kishimoto K, Kinjo F, Fujita J. Impending megacolon: small bowel distension as a predictor of toxic megacolon in ulcerative colitis. Intern Emerg Med. 2012 Oct;7(5):487-8. [PubMed: 22843318]

10.

Berman L, Carling T, Fitzgerald TN, Bell RL, Duffy AJ, Longo WE, Roberts KE. Defining surgical therapy for pseudomembranous colitis with toxic megacolon. J Clin Gastroenterol. 2008 May-Jun;42(5):476-80. [PubMed: 18277885]

11.

Borji S, Rostamian M, Kadivarian S, Kooti S, Dashtbin S, Hosseinabadi S, Abiri R, Alvandi A. Prevalence of Clostridioides difficile contamination in the healthcare environment and instruments: A systematic review and meta-analysis. Germs. 2022 Sep;12(3):361-371. [PMC free article: PMC10482474] [PubMed: 37680683]

12.

Turner NA, Anderson DJ. Hospital Infection Control: Clostridioides difficile. Clin Colon Rectal Surg. 2020 Mar;33(2):98-108. [PMC free article: PMC7042016] [PubMed: 32104163]

13.

Jodorkovsky D, Young Y, Abreu MT. Clinical outcomes of patients with ulcerative colitis and co-existing Clostridium difficile infection. Dig Dis Sci. 2010 Feb;55(2):415-20. [PubMed: 19255850]

14.

Sager K, Alam S, Bond A, Chinnappan L, Probert CS. Review article: cytomegalovirus and inflammatory bowel disease. Aliment Pharmacol Ther. 2015 Apr;41(8):725-33. [PubMed: 25684400]

15.

Garg SR, Sathe PA, Taware AC, Surve KM. Fatal Toxic Megacolon in a Child of Hirschsprung Disease. J Clin Diagn Res. 2016 Dec;10(12):ED03-ED05. [PMC free article: PMC5296439] [PubMed: 28208866]

16.

Argyriou O, Lingam G, Tozer P, Sahnan K. Toxic megacolon. Br J Surg. 2024 Aug 02;111(8) [PubMed: 39120526]

17.

Norland CC, Kirsner JB. Toxic dilatation of colon (toxic megacolon): etiology, treatment and prognosis in 42 patients. Medicine (Baltimore). 1969 May;48(3):229-50. [PubMed: 5769743]

18.

Jalan KN, Sircus W, Card WI, Falconer CW, Bruce CB, Crean GP, McManus JP, Small WP, Smith AN. An experience of ulcerative colitis. I. Toxic dilation in 55 cases. Gastroenterology. 1969 Jul;57(1):68-82. [PubMed: 5305933]

19.

Grieco MB, Bordan DL, Geiss AC, Beil AR. Toxic megacolon complicating Crohn's colitis. Ann Surg. 1980 Jan;191(1):75-80. [PMC free article: PMC1344622] [PubMed: 7352781]

20.

Mourelle M, Casellas F, Guarner F, Salas A, Riveros-Moreno V, Moncada S, Malagelada JR. Induction of nitric oxide synthase in colonic smooth muscle from patients with toxic megacolon. Gastroenterology. 1995 Nov;109(5):1497-502. [PubMed: 7557131]

21.

Tariq S, Farooq A, Ali I, Wijesinghe H. Toxic colonoscopy--how investigating active inflammatory bowel disease can lead to the serious complication of toxic megacolon. BMJ Case Rep. 2015 Jul 22;2015 [PMC free article: PMC4513581] [PubMed: 26202312]

22.

Fabián-Méndez JJ, Torres-Salazar QL. Toxic megacolon: a potentially lethal condition. Case report. J Surg Case Rep. 2024 Jun;2024(6):rjae403. [PMC free article: PMC11165306] [PubMed: 38863961]

23.

Trudel JL, Deschênes M, Mayrand S, Barkun AN. Toxic megacolon complicating pseudomembranous enterocolitis. Dis Colon Rectum. 1995 Oct;38(10):1033-8. [PubMed: 7555415]

24.

Dao QL, Hammad F, Dapaah-Afriyie K. Perforated Toxic Megacolon: The Dreaded Complication in Ulcerative Colitis. J Brown Hosp Med. 2024;3(4):124818. [PMC free article: PMC11864474] [PubMed: 40026558]

25.

Doshi R, Desai J, Shah Y, Decter D, Doshi S. Incidence, features, in-hospital outcomes and predictors of in-hospital mortality associated with toxic megacolon hospitalizations in the United States. Intern Emerg Med. 2018 Sep;13(6):881-887. [PubMed: 29948833]

26.

Bandaru SK. Toxic Megacolon Due to Fulminant Clostridioides difficile Infection. N Engl J Med. 2022 Oct 06;387(14):1309. [PubMed: 36193942]

27.

Imbriaco M, Balthazar EJ. Toxic megacolon: role of CT in evaluation and detection of complications. Clin Imaging. 2001 Sep-Oct;25(5):349-54. [PubMed: 11682295]

28.

Travis SP, Stange EF, Lémann M, Oresland T, Bemelman WA, Chowers Y, Colombel JF, D'Haens G, Ghosh S, Marteau P, Kruis W, Mortensen NJ, Penninckx F, Gassull M., European Crohn's and Colitis Organisation (ECCO). European evidence-based Consensus on the management of ulcerative colitis: Current management. J Crohns Colitis. 2008 Mar;2(1):24-62. [PubMed: 21172195]

29.

Hung CW, Wu WF, Wu CL. Rotavirus gastroenteritis complicated with toxic megacolon. Acta Paediatr. 2009 Nov;98(11):1850-2. [PubMed: 19650837]

30.

Kelly CR, Feuerstadt P. Diagnosis and Management of Clostridioides difficile. Am J Gastroenterol. 2026 Mar 01;121(3):628-634. [PubMed: 41247039]

31.

D'Amico C, Vitale A, Angriman I, Ruffolo C, D'Amico F, Valente D, Berto M, Vella V, Scarpa M, D'Amico DF. Early surgery for the treatment of toxic megacolon. Digestion. 2005;72(2-3):146-9. [PubMed: 16172551]

32.

Lamb CA, Kennedy NA, Raine T, Hendy PA, Smith PJ, Limdi JK, Hayee B, Lomer MCE, Parkes GC, Selinger C, Barrett KJ, Davies RJ, Bennett C, Gittens S, Dunlop MG, Faiz O, Fraser A, Garrick V, Johnston PD, Parkes M, Sanderson J, Terry H, IBD guidelines eDelphi consensus group. Gaya DR, Iqbal TH, Taylor SA, Smith M, Brookes M, Hansen R, Hawthorne AB. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut. 2019 Dec;68(Suppl 3):s1-s106. [PMC free article: PMC6872448] [PubMed: 31562236]

33.

Holubar SD, Lightner AL, Poylin V, Vogel JD, Gaertner W, Davis B, Davis KG, Mahadevan U, Shah SA, Kane SV, Steele SR, Paquette IM, Feingold DL., Prepared on behalf of the Clinical Practice Guidelines Committee of the American Society of Colon and Rectal Surgeons. The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for the Surgical Management of Ulcerative Colitis. Dis Colon Rectum. 2021 Jul 01;64(7):783-804. [PubMed: 33853087]

34.

Danovitch SH. Fulminant colitis and toxic megacolon. Gastroenterol Clin North Am. 1989 Mar;18(1):73-82. [PubMed: 2493427]

35.

Ahmed N, Kuo YH. Early Colectomy Saves Lives in Toxic Megacolon Due to Clostridium difficile Infection. South Med J. 2020 Jul;113(7):345-349. [PubMed: 32617595]

36.

Pumiglia L, Wilson L, Rashidi L. Clostridioides difficile Colitis. Surg Clin North Am. 2024 Jun;104(3):545-556. [PubMed: 38677819]

37.

De Giorgio R, Sarnelli G, Corinaldesi R, Stanghellini V. Advances in our understanding of the pathology of chronic intestinal pseudo-obstruction. Gut. 2004 Nov;53(11):1549-52. [PMC free article: PMC1774265] [PubMed: 15479666]

38.

Greenstein AJ, Sachar DB, Gibas A, Schrag D, Heimann T, Janowitz HD, Aufses AH. Outcome of toxic dilatation in ulcerative and Crohn's colitis. J Clin Gastroenterol. 1985 Apr;7(2):137-43. [PubMed: 4008909]

39.

Flatmark A, Fretheim B, Gjone E. Early colectomy in severe ulcerative colitis. Scand J Gastroenterol. 1975;10(4):427-31. [PubMed: 1153936]

Disclosure: Eric Goosenberg declares no relevant financial relationships with ineligible companies.

Disclosure: Jose Pico declares no relevant financial relationships with ineligible companies.